A Phase II Clinical Trial of Flutamide in the Treatment of Advanced Breast Cancer

@article{Zhao1988API,
  title={A Phase II Clinical Trial of Flutamide in the Treatment of Advanced Breast Cancer},
  author={Tiping Zhao and G F He},
  journal={Tumori Journal},
  year={1988},
  volume={74},
  pages={53 - 56}
}
  • T. Zhao, G. He
  • Published 1 February 1988
  • Medicine, Biology
  • Tumori Journal
An antiandrogenic agent flutamide was used in the treatment of one male and 14 female postmenopausal breast cancer patients. Only a mild and transient response was seen in 2 female patients. Therefore, flutamide cannot be used solely in the treatment of female postmenopausal breast cancer. 

Tables from this paper

Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer
TLDR
The CBR of 19% observed with bicalutamide shows proof of principle for the efficacy of minimally toxic androgen blockade in a select group of patients with ER/PgR-negative, AR-positive breast cancer.
New Entrants into Clinical Trials for Targeted Therapy of Breast Cancer: An Insight.
TLDR
This review highlights the recently studied target molecules that have received indications in breast carcinoma, both in the localized and in advanced state and about their inhibitors which are in clinical development which can give immense potential to clinical care in the near future.
Growth inhibition of DMBA-induced rat mammary carcinomas by the antiandrogen flutamide
TLDR
It is demonstrated that the antiandrogen FLU and the full androgen DHT exert similar inhibitory effects on the growth of dimethylbenz(a)anthracene (DMBA)-induced rat mammary tumors, and data show that plasma steroids levels are unaffected by FLU treatment.
Role of the androgen receptor in triple-negative breast cancer.
TLDR
Despite lower pathologic complete response (pCR) rates with neoadjuvant therapy, patients with AR-dependent TNBCs have a better prognosis than those with T NBCs that are not AR- dependent, and this paper describes the results of early clinical trials with antiandrogens in this population.
Inhibitory effect of hydroxyflutamide plus tamoxifen on oestradiol-induced growth of MCF-7 breast cancer cells
TLDR
The antiproliferative effect of hydroxyflutamide, without virilizing side-effects, suggests that it is worth exploring its possible employment together with antioestrogens in the treatment of breast cancer patients.
The Role of Androgen Receptor in Breast Cancer.
The Role of Androgen Receptor Signalling in Endocrine Resistant Breast Cancer
TLDR
Understanding of the role of the AR in BCa progression is further understood and it is suggested that it is a valid therapeutic target to prevent and/or treat endocrine resistant disease.
...
...

References

SHOWING 1-7 OF 7 REFERENCES
Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy
TLDR
Flutamide appears to be a safe antiandrogen, usually effective in the management of patients with advanced prostatic cancer who have had no prior endocrine therapy.
Androgen receptors in breast cancer
TLDR
Patients who had received tamoxifen as treatment for advanced disease were assessed for objective response and androgen receptor data added significantly to the information provided by estrogen receptors both in terms of response to hormone treatment and survival.
The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture.
TLDR
Examination of human breast cancer cell lines in continuous tissue culture for androgen responsiveness and cross-competition studies provides compelling evidence that some human breasts, at least in vitro, may be androgen dependent.
Increased androgenic activity and breast cancer risk in premenopausal women.
TLDR
Evidence is provided for the hypothesis that increased androgenic activity is an important risk indicator for breast cancer, particularly when associated with anovulation, as indicated by low serum progesterone level.
Circulating levels of testosterone, 17 beta-oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients.
TLDR
The results confirm the previous findings of increased urinary testosterone values in postmenopausal breast cancer patients and support the hypothesis that androgens may play a role in the development of breast cancer.
Aromatase in human breast carcinoma.
TLDR
In this study, aromatase was examined in homogenates of breast adipose and breast carcinoma tissue, in normal and abnormal parenchymal breast tissue, and in Breast carcinoma cells in culture.
Circulating levels of testosterone, 17~Zhao and He group
  • Br. J. Cancer,
  • 1983